Fosfemen Injection 0.5 grams (Meropenem Trihydrate)

Adult administration

As meropenem hydrate, administer 0.5 to 1 g (potency) daily divided into 2 to 3 doses by intravenous drip over more than 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) intravenously every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) intravenously every 8 hours.

Child administration

For bacterial meningitis in children over 3 months, administer by intravenous drip over more than 30 minutes, 40 mg per kg of body weight every 8 hours based on the sensitivity of the pathogen and the patient’s condition, as well as the type of infection. Severe.

This medication should not be used in patients who have experienced shock due to this drug in the past. Additionally, patients taking valproate sodium should be cautious when using this drug together, as it may lower the blood concentration of valproate and lead to recurrence of seizures. Patients with allergies or hypersensitivity to this drug or its ingredients, as well as those who have had severe allergic reactions to other carbapenem or beta-lactam antibiotics should not receive this medication. Patients with allergic tendencies or a family history of allergic symptoms such as bronchial asthma or rashes should use this drug with caution. Patients with poor kidney function may experience prolonged retention of this drug in the body, which can lead to central nervous system symptoms such as seizures or consciousness disorders, requiring dosage or administration interval adjustments. Patients with epilepsy or central nervous system disorders may also be at risk for seizures or consciousness disorders, so they should be careful. Patients with severely impaired liver function should be cautious as the condition may worsen. The elderly may have decreased physical functions, requiring careful observation and adjustment of dosage and administration intervals due to a higher likelihood of side effects. Patients with poor nutritional status or an inability to take oral intake may exhibit vitamin K deficiency symptoms, necessitating special monitoring. This medication has not established safety and efficacy in infants under 3 months, so caution is required for use. During administration of this drug, shock or anaphylaxis reactions may rarely occur; therefore, patients should be monitored closely, and if symptoms such as discomfort, difficulty breathing, dizziness, sweating, etc. occur, administration should cease immediately and appropriate treatment should be initiated. Hypersensitivity reactions such as skin rash, urticaria, itching, fever may also manifest; if such symptoms arise, medication should be discontinued, and treatment should be sought. Regular blood tests are necessary as blood anomalies such as leukopenia, anemia, and platelet changes may occur; if abnormalities arise, administration should be suspended. Liver function tests are also required, and if hepatitis or liver dysfunction symptoms appear, the drug should be stopped. Regular kidney function tests should be conducted as kidney function may suddenly decline; if abnormalities are found, administration should cease. Gastrointestinal issues such as severe diarrhea, abdominal pain, nausea, vomiting should be promptly communicated to a physician when symptoms occur. Central nervous system symptoms such as seizures or consciousness disturbances may occur, so patients with neurological diseases should be particularly cautious. Respiratory anomalies such as asthma attacks, difficulty breathing, pneumonia may rarely occur, thus immediate treatment is required when symptoms develop. Serious skin reactions like Stevens-Johnson syndrome, toxic epidermal necrolysis, and other severe skin responses may appear, necessitating close observation of skin conditions. Additionally, symptoms of microbial shifts such as stomatitis or candidiasis may occur rarely. There may be a tendency for bleeding due to vitamin K deficiency, so bleeding symptoms should be monitored closely. Cardiovascular abnormalities such as heart failure, cardiac arrest, arrhythmias have been reported; therefore, individuals with heart diseases should be cautious. Neuropsychiatric symptoms such as insomnia, mental confusion, dizziness may appear, so consultation with a physician is recommended if abnormal symptoms arise. Inflammation, pain, or swelling at the injection site may occur; therefore, injection sites should be carefully monitored. This drug interacts with various other medications, especially probenecid, antiepileptics, contraceptives, and warfarin, therefore caution should be exercised, and blood tests should frequently confirm the status. Women who are pregnant or may become pregnant should use this medication only when the therapeutic benefits outweigh the risks due to the lack of established safety. Lactating women should avoid breastfeeding since this drug may be secreted into breast milk. This medication should be administered only intravenously, and it’s advisable to use it as soon as possible after dissolving it. Additionally, this drug may have cross-allergy with other beta-lactam antibiotics; therefore, it is essential to inform of any previous allergies to such drugs.

Serious side effects

Shock, anaphylactic-like reactions, severe skin reactions (toxic epidermal necrolysis, mucocutaneous syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis), severe allergic reactions, severe skin adverse reactions, liver failure, jaundice, acute renal failure, severe kidney damage, severe colitis (pseudomembranous colitis), asthma, difficulty breathing, increased coughing, interstitial pneumonia, pulmonary edema, PIE syndrome, seizures, consciousness disorders, central.

Mild side effects

• Oral discomfort
• wheezing
• dizziness
• diarrhea
• tinnitus
• sweating
• rash
• heat sensation
• erythema
• itching

This medication should be stored in a sealed container to prevent air from entering and kept at room temperature between 1 to 30 degrees Celsius. By doing so, the efficacy of the drug can be maintained for a longer duration.

Appearance

A vial filled with crystalline powder ranging from white to yellowish.

Package unit

10 vials